Mesothelioma: Current Trials and Innovations in Patient Matching

The diagnostic odyssey

Mesothelioma, a rare and aggressive cancer primarily associated with asbestos exposure, presents significant challenges in both diagnosis and treatment. Patients often experience a prolonged diagnostic journey due to the disease's non-specific symptoms, which can mimic those of other conditions. As a result, many eligible patients remain undiagnosed or misdiagnosed for extended periods, complicating their access to potentially life-saving clinical trials. The rarity of mesothelioma exacerbates this issue, making it crucial to identify and enroll patients who meet the specific criteria for ongoing research studies.

The trial landscape right now

Currently, there are 16 recruiting clinical trials for mesothelioma across 79 sites in four countries. The trials are predominantly in the United States (64 sites), with additional locations in China (10), Belgium (3), and Italy (2). The phase mix includes 8 Phase II trials, 4 N/A trials, and 4 Phase I trials. Notable sponsors include the National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, and the Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Among these trials, several are noteworthy:

• NCT03683680 investigates the prognostic biomarkers for malignant pleural mesothelioma through prospectively collected pleural biopsies.
• NCT05001880 evaluates the efficacy of chemotherapy with or without immunotherapy for peritoneal mesothelioma in a Phase II setting.
• NCT05188859 tests a combination of sintilimab, anlotinib, and platinum doublet chemotherapy for malignant pleural mesothelioma, sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences in China.

These trials reflect the ongoing efforts to improve treatment outcomes and provide innovative therapeutic options for patients battling this challenging disease.

How we detect the match

Innovations in healthcare integration, specifically through HL7 and FHIR standards combined with AI capabilities, are transforming how we identify eligible patients for clinical trials. By leveraging existing clinical data without the need for manual chart reviews, healthcare systems can streamline patient matching. For instance, FHIR resources such as Condition, Observation, MedicationRequest, and DiagnosticReport can be utilized to extract relevant patient information.

Through the analysis of lab results, genetic markers, and ICD-10 diagnoses, computable phenotypes can be created to identify individuals with mesothelioma. This automated approach reduces the time and labor involved in patient identification, allowing for a more efficient recruitment process in clinical trials. By integrating these technologies, healthcare providers can significantly enhance the precision of patient matching and improve trial enrollment rates.

Beyond the trial: better care

The integration of HL7 and FHIR standards not only facilitates trial enrollment but also enhances overall patient care. By employing an AI-driven approach to analyze patient data, healthcare providers can shorten the diagnostic odyssey for mesothelioma patients. This proactive identification of eligible patients allows for timely referrals to specialists and clinical trials, ultimately improving care coordination and monitoring.

Moreover, even for patients who do not enroll in trials, these integrated systems can provide better management of their condition by ensuring that healthcare providers have access to comprehensive patient data. This access allows for more informed decision-making and tailored treatment plans, thereby enhancing the quality of care for all patients with mesothelioma.

The takeaway

Mesothelioma remains a complex challenge in oncology, characterized by a difficult diagnostic journey and limited treatment options. However, the landscape of clinical trials is evolving, with numerous studies underway aimed at improving outcomes. The integration of HL7 and FHIR standards with AI technologies presents a promising solution for identifying eligible patients efficiently, ultimately leading to better care and improved patient outcomes.